<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859986</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-101-ATOP-204</org_study_id>
    <nct_id>NCT03859986</nct_id>
  </id_info>
  <brief_title>Study in Subjects With Moderate Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ralexar Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ralexar Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to&#xD;
      evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when&#xD;
      applied topically twice daily for 56 days in adult and adolescent subjects with moderate&#xD;
      atopic dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are to:&#xD;
&#xD;
        -  Evaluate the safety of ALX-101 Gel 5% when applied topically twice daily in subjects&#xD;
           with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle&#xD;
&#xD;
        -  Evaluate the efficacy of ALX-101 Gel 5% when applied topically twice daily in subjects&#xD;
           with moderate atopic dermatitis compared with a matching ALX-101 Gel Vehicle&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area Severity Index (EASI)</measure>
    <time_frame>Day 57</time_frame>
    <description>Mean change from baseline in EASI score at Week 8</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Atopic Dermatitis Eczema</condition>
  <arm_group>
    <arm_group_label>ALX-101 Gel 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALX-101 Gel 5% applied topically twice daily for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-101 Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ALX-101 Gel Vehicle applied topically twice daily for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX-101 Gel Vehicle</intervention_name>
    <description>ALX-101 Gel Vehicle</description>
    <arm_group_label>ALX-101 Gel Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALX-101 Gel 5%</intervention_name>
    <description>ALX-101 Gel 5%</description>
    <arm_group_label>ALX-101 Gel 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 12 years of age at the time of consent.&#xD;
&#xD;
          2. Subject has a clinical diagnosis of stable AD confirmed using the Hanafin and Rajka&#xD;
             criteria&#xD;
&#xD;
          3. Subject has at least a 6-month history of atopic dermatitis and had no significant&#xD;
             flares in atopic dermatitis for at least 4 weeks before Visit 1 (screening)&#xD;
             (information obtained from medical chart or subject's physician or directly from the&#xD;
             subject).&#xD;
&#xD;
          4. Subject must have active features of AD covering a minimum of 2% body surface area&#xD;
             (BSA) (excluding scalp, face, genitals, palmar aspect of hands and plantar aspect of&#xD;
             feet) at Visit 2 (baseline).&#xD;
&#xD;
          5. Subject has moderate AD, defined as vIGA-AD™ score of 3 (&quot;moderate&quot;), at Visit 2&#xD;
             (baseline).&#xD;
&#xD;
          6. Subject has an EASI score ≥ 5 at Visit 2 (baseline)&#xD;
&#xD;
          7. Subject has been using an emollient (except those containing urea) daily for at least&#xD;
             1 week prior to Visit 2 (baseline), except on visit day before the visit. Subject&#xD;
             agrees to continue using that emollient, daily at the same frequency, on non-treated&#xD;
             areas, throughout the study but not the day of visits prior to the visit scheduled&#xD;
             time.&#xD;
&#xD;
          8. Female subject of childbearing potential involved in any sexual intercourse that could&#xD;
             lead to her pregnancy, must have a negative serum pregnancy test at Visit 1, a&#xD;
             negative urine pregnancy test at Visit 2 (baseline) and agree to use an approved&#xD;
             highly effective contraceptive method for the entire study and up to 4 weeks following&#xD;
             the final dose of study medication unless they are surgically sterile (hysterectomy,&#xD;
             bilateral oophorectomy, or bilateral salpingectomy) or in menopausal state for at&#xD;
             least one year prior to screening (Visit 1)&#xD;
&#xD;
          9. Male subject of childbearing potential agree to use an approved highly effective&#xD;
             method of contraception through study participation for 4 weeks following the final&#xD;
             dose of study medication&#xD;
&#xD;
         10. Subject is in good general health and free of any known disease state or physical&#xD;
             condition which, in the investigator's opinion, might impair evaluation of the AD&#xD;
             being treated or which exposes the subject to an unacceptable risk by study&#xD;
             participation&#xD;
&#xD;
         11. Subject is willing and able to follow all study instructions and to attend all study&#xD;
             visits&#xD;
&#xD;
         12. Subject is able to comprehend and willing to sign an Informed Consent Form&#xD;
             (ICF)/Assent Form (AF)&#xD;
&#xD;
         13. Parent/guardian has the ability to understand, agree to and sign the study Informed&#xD;
             Consent Form (ICF) prior to initiation of any protocol-related procedures as&#xD;
             applicable; subject has the ability to give assent in the Assent Form (AF)&#xD;
&#xD;
         14. Informed Consent Form (ICF)/Assent Form (AF) must be obtained prior to initiation of&#xD;
             any protocol-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has spontaneously improving or rapidly deteriorating AD&#xD;
&#xD;
          2. Subject has clinically infected AD&#xD;
&#xD;
          3. Subject has any signs or symptoms associated with topical AD therapy which, in the&#xD;
             investigator's opinion, might impair evaluation of the AD being treated or which&#xD;
             exposes the subject to an unacceptable risk by study participation&#xD;
&#xD;
          4. Subject has any clinically significant laboratory abnormality, medical condition or&#xD;
             physical/vital signs abnormality that would, in the opinion of the investigator, put&#xD;
             the subject at undue risk or interfere with interpretation of study results&#xD;
&#xD;
          5. Subjects with a past history of cancer or lymphoproliferative disease within 5 years&#xD;
             prior to Visit 2 (baseline) (subjects with successfully treated non-metastatic&#xD;
             cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of&#xD;
             the cervix are not to be excluded)&#xD;
&#xD;
          6. Subject is known to have immune deficiency or is immunocompromised&#xD;
&#xD;
          7. Subject has a known history of chronic infectious disease (e.g., hepatitis B,&#xD;
             hepatitis C, or infection with human immunodeficiency virus)&#xD;
&#xD;
          8. Subject had major surgery within 8 weeks prior to Visit 2 (baseline) or has a major&#xD;
             surgery planned during the study.&#xD;
&#xD;
          9. Topical medications, including but not limited to, topical corticosteroids,&#xD;
             crisaborole and any other topical phosphodiesterase-4 inhibitor, calcineurin&#xD;
             inhibitors, tars, bleach, antimicrobials, medical devices and bleach bath within 2&#xD;
             weeks prior to Visit 2 (baseline)&#xD;
&#xD;
         10. Subject has used any non-medicated topical product (e.g., lotions, gels, creams,&#xD;
             ointments) in the planned treatment area 4 hours prior to Visit 2 (baseline)&#xD;
&#xD;
         11. Subject has used the following systemic treatments (other than biologics) that could&#xD;
             affect atopic dermatitis less than 4 weeks prior to Visit 2 (baseline) (e.g.,&#xD;
             retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide&#xD;
             [hydroxyurea], azathioprine, oral/injectable corticosteroids) within 4 weeks prior to&#xD;
             Screening. Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and&#xD;
             ear drops containing corticosteroids are also allowed.&#xD;
&#xD;
         12. Subject has used any systemic antibiotics within 2 weeks prior to Visit 2 (baseline)&#xD;
&#xD;
         13. Subject has used hydroxyzine or diphenhydramine within 1 week prior to Visit 2&#xD;
             (baseline), unless on a stable dose.&#xD;
&#xD;
         14. Subject has used topical doxepin within 1 week prior to Visit 2 (baseline).&#xD;
&#xD;
         15. Subject has used topical products containing urea within 1 week prior to Visit 2&#xD;
             (baseline)&#xD;
&#xD;
         16. Subject has used or is planning to use any phototherapy (e.g., UVA/UVB therapy, or&#xD;
             PUVA therapy), excessive natural or artificial ultraviolent radiation (e.g., sunlight,&#xD;
             tanning beds) which, in the investigator's opinion, might affect AD within 4 weeks&#xD;
             prior to Visit 2 (baseline)&#xD;
&#xD;
         17. Biologic therapies (e.g., Dupilumab) within 12 weeks or 5 half-lives prior to Visit 2&#xD;
             (baseline)&#xD;
&#xD;
         18. Subject has a history of sensitivity to any of the ingredients in the study&#xD;
             medications&#xD;
&#xD;
         19. Subject has any known concomitant dermatologic or medical condition which, in the&#xD;
             investigator's opinion, might impair evaluation of the areas of AD being treated or&#xD;
             which exposes the subject to an unacceptable risk by study participation (e.g.,&#xD;
             psoriasis, rosacea, lichen planus, lichen simplex chronicus,…)&#xD;
&#xD;
         20. Subject is a female who is breastfeeding, pregnant, or who is planning to become&#xD;
             pregnant during the study.&#xD;
&#xD;
         21. Subject has a known history of clinically significant drug or alcohol abuse in the&#xD;
             last year prior to Visit 2 (baseline)&#xD;
&#xD;
         22. Subject has participated in a nonbiological investigational drug trial in which&#xD;
             administration of an investigational study medication occurred within 4 weeks prior to&#xD;
             Visit 2 (baseline)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ralexar Investigational Site 10</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 5</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 3</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 2</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 22</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 18</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 6</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 13</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 7</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 21</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 1</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 17</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 12</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 14</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 8</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 9</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 19</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 16</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 4</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 15</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 20</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralexar Investigational Site 11</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

